Second-generation antipsychotics (SGAs) are the cornerstone of treatment for schizophrenia
because of their high clinical efficacy. However, SGA treatment is associated with severe …

A substantial and diverse body of literature suggests that the pathophysiology of
schizophrenia is related to deficits of bioenergetic function. While antipsychotics are an …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Background Schizophrenia, bipolar disorder and depression are associated with
inflammation. However, it is unclear whether associations of immunological proteins/traits …

AIM To compare the prevalence of diabetes in patients with schizophrenia treated at a
community mental health center with controls in the same metropolitan area and to examine …

People with psychotic disorders show abnormalities in several organ systems in addition to
the central nervous system (CNS); and this contributes to excess mortality. However, it is …

Importance Schizophrenia and major depressive disorder (MDD) are associated with
increased risks of immunologic disease and metabolic syndrome. It is unclear to what extent …

Background The extent of metabolic and lipid changes in first-episode psychosis (FEP) is
unclear. Aims To investigate whether individuals with FEP and no or minimal antipsychotic …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Background Dyslipidaemia is one of the most prevalent metabolic disturbances observed in
schizophrenia patients and has been largely attributed to the effects of poor lifestyle habits …